淋巴细胞免疫治疗对复发性流产的诊疗效果评价  

Evaluation of the diagnostic and therapeutic effects of lymphocyte immunotherapy on recurrent miscarriage

作　　者：解磊[1] 王鑫[1] 张晓冬 谷小乐 赵丽娟[1] XIE Lei;WANG Xin;ZHANG Xiao-dong(Center for Research in Reproductive Medicine of Shandong University/National Engineering Research Center for Assisted Reproduction and Eugenics/Ministry of Education Key Laboratory of Reproductive Endocrinology(Shandong University),Shandong Ji'nan 250001)

机构地区：[1]山东大学生殖医学研究中心/国家辅助生殖与优生工程技术研究中心/生殖内分泌教育部重点实验室(山东大学),山东济南250001

出　　处：《医学检验与临床》2024年第5期41-45,共5页Medical Laboratory Science and Clinics

摘　　要：目的:分析复发性流产患者经淋巴细胞主动免疫治疗后的临床结局,探讨免疫治疗的效果及适应症。方法:选择2017年1月-2020年12月在山东大学附属生殖医院接受淋巴细胞免疫治疗的625例复发性流产患者作为研究对象。按照致病因素分组,分析不同组别复发性流产(RSA)患者的治疗效果。结果:接受淋巴细胞免疫治疗的625例复发性流产患者,免疫因素RSA患者成功分71例(57.26%),其他因素导致的RSA患者成功分娩38例(41.30%),原因不明复发性流产(URSA)患者成功分娩229例(55.99%)。三组疗效间存在显著统计学差异(P<0.05)。接受免疫治疗的625例复发性流产患者中有17例(2.72%)出现皮肤过敏、发热等不良反应,但未对临床妊娠结局造成影响。结论:接受淋巴细胞免疫治疗的RSA患者人群中,免疫因素RSA患者组和URSA患者组,与其他因素导致的RSA患者组相比,有更好的治疗效果。淋巴细胞免疫治疗对于免疫功能紊乱的RSA患者及URSA患者的治疗效果是安全和有效的。Objective:Analyze the clinical outcomes of patients with recurrent miscarriage after active lymphocyte immunotherapy,and explore the effectiveness and indications of immunotherapy.Methods:625 patients with recurrent miscarriage who received lymphocyte immunotherapy at the Afiliated Reproductive Hospital of Shandong University from January 2017 to December 2020 were selected as the research subjects.Analyze the treatment effects of different groups of patients with recurrent miscarriage(RSA)according to the grouping of pathogenic factors.Results:Among the 625 patients with recurrent miscarriage who received lymphocyte immunotherapy,71(57.26%)were successfully delivered due to immune factors in RSA patients,38(41.30%)were successfully delivered due to other factors in RSA patients,and 229(55.99%)were successfully delivered due to unexplained recurrent miscarriage(URSA)patients.There was a significant statistical difference(P<0.05)in the efficacy among the three groups.Out of 625 patients with recurrent miscarriage who received immunotherapy,17(2.72%)experienced adverse reactions such as skin allergies and fever,but did not affect clinical pregnancy outcomes.Conclusion:In the population of RSA patients receiving lymphocyte immunotherapy,the immune factor RSA patient group and URSA patient group have better therapeutic effects compared to the RSA patient group caused by other factors.The therapeutic effect of lymphocyte immunotherapy is safe and effective for RSA patients and URSA patients with immune dysfunction.

关 键 词：复发性流产 淋巴细胞免疫治疗 妊娠结局 

分 类 号：R446.6[医药卫生—诊断学]